CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 318 enrolled
Drug / intervention
PF-04217329 - Lowest Dose +20 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00572455
NCT00572455Phase 2Completed
CompareCT.gov

A 2-STAGE, PHASE 2, DOUBLE-MASKED, RANDOMIZED, VEHICLE CONTROLLED, DOSE RESPONSE TRIAL OF PF-04217329 AND THE MARKETED FORMULATION OF LATANOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Pfizer·interventional·Posted Dec 13, 2007·Updated Apr 30, 2021

In Brief

A Phase 2 clinical trial evaluating PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, and 7 other interventions for Primary Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 318 participants across 23 sites.

Detailed Summary

To evaluate the safety and efficacy of PF-04217329.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open-Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 13, 2007
Enrollment StartDec 11, 2007
Primary CompletionJun 26, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.6 years ago

Interventions

PF-04217329 - Lowest Dosedrug

1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.

PF-04217329 - Low Dosedrug

1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.

PF-04217329 - Middle Dosedrug

1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.

PF-04217329 - High Middle Dosedrug

1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.

PF-04217329 - High Dosedrug

1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.

PF-4217329 - Highest Dosedrug

1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.

PF-04217329 - Vehicledrug

1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.

Latanoprost Vehicledrug

1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.

PF-04217329 - Low Dosedrug

Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost Vehicledrug

1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.

PF-04217329 - Middle Dosedrug

Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost Vehicledrug

1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.

PF-04217329 - High Dosedrug

Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost 0.005%drug

1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.

PF-04217329 - Low Dosedrug

Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost 0.005%drug

1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.

PF-04217329 - Middle Dosedrug

Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost 0.005%drug

1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.

PF-04217329 - High Dosedrug

Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.

Latanoprost 0.005%drug

1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.

PF-04217329 - Vehicledrug

Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.